Skip to content

Immune-Related Adverse Events: Findings From a Population-Based Study.

Nov 2026 · Journal of immunotherapy · 0 citations · 24 references
Medicine

TL;DR

Nearly half of patients experienced at least one hospitalization with an irAE recorded as the main discharge diagnosis within 6 months after ICI initiation, underscoring the importance of monitoring and management to reduce patient and healthcare impact.

Abstract

Immune checkpoint inhibitors (ICIs) are effective for several tumor entities but cause immune-related adverse events (irAEs). These side effects may affect any organ and often lead to ICI discontinuation, hospitalization, long-term complications, or sequelae. To assess the burden of irAEs, this longitudinal observational study analyzed their incidence and the frequency of related hospitalizations using anonymized health claims data from a payer database covering 5.8 million insured individuals in Germany. Patients with hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), renal cancer, urothelial cancer, or skin cancer who started ICI therapy between 2017 and 2020 were selected using ICD-10 GM (International Statistical Classification of Diseases, German Modification) codes. The incidence of irAEs and related hospitalizations within 6 months was assessed using predefined ICD-10 codes in both inpatient and outpatient settings. A total of 6350 patients (mean age: 66.8 y) with NSCLC (n=4797), skin cancer (n=1266), HCC (n=1249), renal (n=1183), or urothelial cancer (n=656) initiated ICI therapy between 2017 and 2020. The incidence of any new-onset irAE was 31.4% (95% CI: 30.3%-32.6%). New-onset respiratory irAEs were the most common [11.7% (95% CI: 11.0%-12.5%)], followed by gastrointestinal irAEs (7.8%; 95% CI: 7.1%-8.5%). Skin cancer patients most frequently developed gastrointestinal irAEs, while other tumor types showed more respiratory irAEs. Using an inclusive definition that also captures exacerbations of pre-existing conditions, nearly half of patients experienced at least one hospitalization with an irAE recorded as the main discharge diagnosis within 6 months after ICI initiation. These findings underscore the importance of monitoring and management to reduce patient and healthcare impact.

View source

Similar papers

Open access Oct 2026

IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY

Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs). Data regarding immunotherapy safety in elderly patients remain limited. This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients...

Buket Şahin Çelik, H. Ertas, Gözde Ağdaş · 0 citations
Open access Oct 2026

Checkpoint inhibitors and chronic comedications: A retrospective study on immune-related adverse events.

In this cohort, irAE were highly prevalent and pembrolizumab-treated patients were predominant and chronic co-medications were not associated with the occurrence of irAE, however, the design of the study, short follow-up and limited sample size may have limited the detection of an effect.

Margot Vattaire-Hervé, C. Barbe, L. Bouazzi et al. · 0 citations
Review Open access Oct 2026

Real-world cardiovascular toxicity of immune checkpoint inhibitors in an asian population: insights from a nationwide taiwanese registry

Immune checkpoint inhibitors (ICIs) have revolutionized oncologic treatment but are increasingly recognized to be associated with immune-related cardiovascular (CV) toxicities. While most epidemiological data were derived from Western populations, comprehensive real-world data from Asian cohorts remain limited. T...

K. Chen, W. Chang, Y. Chen et al. · 0 citations
Open access 2026

Efficacy and adverse reaction risk factors of immunotherapy in advanced non-small cell lung cancer: a retrospective study.

OBJECTIVE To evaluate the clinical efficacy of programmed cell death 1 (PD-1) inhibitors and identify risk factors for immune-related adverse reactions (irAEs) in patients with advanced non-small cell lung cancer (NSCLC). METHODS A retrospective analysis was performed on data from 224 advanced NSCLC patients treated...

Qian-Wen Gao, Lin Jin · 0 citations
Nov 2026

Abstract 10388: Characterizing Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicity: A 12-Year Real-World Analysis of Incidence, ICI Class, and Cancer-Type Variation

Background: Cardiovascular disease is the leading cause of non-cancer mortality in cancer survivors.1 Immune checkpoint inhibitors (ICIs) are associated with cardiovascular toxicity, but real-world burden across ICI classes and cancer types remains poorly characterized.2-4 Aims: To characterize the incidence a...

Christabelle Junaidi, B. Schulte · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.